AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 34864978
Drug: Ultraslow thrombolytic
RxNorm normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultraslow thrombolytic regimen (25 mg of rtPA infused in 25 hours)
Trial: 34864978
Drug: Fast thrombolytic
RxNorm normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fast thrombolytic regimen (50 mg of rtPA infused in 6 hours)
Trial: 34162831
Drug: Clinical-stage orally
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinical-stage orally administered drugs targeting inhibitor of apoptosis proteins
Trial: 36321647
Drug: Calcipotriol‐Betamethasone Dipropionate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcipotriol‐Betamethasone Dipropionate (Cal/BD) foam with Ablative Fractional Laser (AFL) treatment
Trial: 32138709
Drug: Propranolol treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol treatment in children with long-QT syndrome
Trial: 83012907
Drug: Propoxyphene napsylate
RxNorm normalized name: Propoxyphene Napsylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propoxyphene napsylate (PN) 800 mg in two divided doses
Trial: 34431926
Drug: Slow injection
RxNorm normalized name: Slow Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow injection with aspiration
Trial: 33745625
Drug: High Protein
RxNorm normalized name: Vital High Protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High Protein group (1.6 g of protein/kg/day)
Trial: 33745625
Drug: Low Protein
RxNorm normalized name: Low protein mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low Protein group (0.8 g of protein/kg/day)
Trial: 35346353
Drug: Resistance exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resistance exercise program (60 min, once a week for 12 weeks, and self-exercise twice a week)
Trial: 32430078
Drug: Supervised exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supervised exercise program (bi-weekly) including aerobic training, strengthening, and cardiovascular exercises for 8 weeks.
Trial: 34737064
Drug: Sprifermin (recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sprifermin (recombinant FGF18), administered intra-articularly over a 2-year period.
Trial: 34737064
Drug: Placebo, administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, administered intra-articularly over a 2-year period.
Trial: 34091813
Drug: Sublingual dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Sublingual dexamethasone 8 mg (2 ml) with normal saline administered 1 hour before surgery
Trial: 34091813
Drug: Intramuscular dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intramuscular dexamethasone 8 mg
Trial: 35272334
Drug: Methenamine with
RxNorm normalized name: Methenamine
DrugBank: Methenamine (DB06799)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methenamine with cranberry capsules
Trial: 32701140
Drug: Standard-of-care neoadjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-of-care neoadjuvant therapy consisting of taxane treatment followed by doxorubicin and cyclophosphamide.
Trial: 32701140
Drug: Control therapy
RxNorm normalized name: Benzoyl Peroxide;Salicylic Acid;Vitamin E 8%; 2%; 5% Topical application Kit [INOVA 8/2 ACNE CONTROL THERAPY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control therapy (taxane treatment without investigational agents).
Trial: 32584180
Drug: butorphanol tartrate
RxNorm normalized name: Butorphanol Tartrate
DrugBank: Butorphanol (DB00611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: butorphanol tartrate (5 mg/kg)
Trial: 35380376
Drug: Dexmedetomidine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (1 µg/kg) with ketamine (0.5 mg/kg) administered over 10 min followed by a maintenance dose of Dexmedetomidine (0.2‐0.8 µg/kg/h)
Trial: 33016783
Drug: Herceptin® (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Herceptin® (6 mg/kg)
Trial: 35545356
Drug: Mindfulness-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness-based cognitive therapy (MBCT) as an addition to usual care
Trial: 33150320
Drug: Comparator vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparator vaccine
Trial: 35027515
Drug: Goal-directed therapy
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Goal-directed therapy (GDT) protocol using DCO2 and SCvo2
Trial: 33345953
Drug: 100% oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100% oxygen at 10 L/min until delivery
Trial: 35222905
Drug: Whole-body photobiomodulation
RxNorm normalized name: Insects (whole body), mite dermatophagoides farinae
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole-body photobiomodulation (PBM) therapy programme
Trial: 32461138
Drug: High-dose vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose vitamin D (25,000 IU weekly for 26 weeks)
Trial: 33606419
Drug: Predetermined volumes
RxNorm normalized name: VOLUME EXPANDERS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Predetermined volumes of a feeding-drink (Nutricia Nutridrink) between 50 and 400 ml
Trial: 33780930
Drug: Experimental group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental group increased TWI to 3.7 L for males and 2.7 L for females for 14 days.
Trial: 36695682
Drug: High-dose cholecalciferol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose cholecalciferol
Trial: 33339752
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment for 14 days
Trial: 33031270
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg of VASO6 (green tea extract)
Trial: 33956802
Drug: Routine treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine treatment supervision (control)
Trial: 33109386
Drug: Hetrombopag 7.5-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hetrombopag 7.5-mg tablets administered with high-fat, high-calorie food
Trial: 33109386
Drug: Hetrombopag 7.5-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hetrombopag 7.5-mg tablets administered in the fasted state
Trial: 34287856
Drug: Parenteral anticoagulation
RxNorm normalized name: CPDA-1 Anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral anticoagulation therapy (PACT)
Trial: 34290173
Drug: Verapamil 2.5
RxNorm normalized name: verapamil 2.5 mg/mL intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil 2.5 mg
Trial: 32727162
Drug: 6 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 g/day Fish Oil (FO)
Trial: 35130935
Drug: TtLIVE intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TtLIVE intervention (multi-component virtual care solution including virtual home visits, customizable care plans, clinical workflows, digitally secure communication, resource library)
Trial: 33527139
Drug: Standard glucocorticoid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard glucocorticoid therapy
Trial: 34049911
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment plus calcium dobesilate (CaD) 500 mg three times per day for 12 months
Trial: 33742792
Drug: Therapeutic touch
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic touch (TT) as a complementary therapy
Trial: 32864805
Drug: Single-agent concurrent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-agent concurrent chemoradiotherapy using S-1
Trial: 32864805
Drug: Double-agent concurrent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double-agent concurrent chemoradiotherapy using S-1 and cisplatin
Trial: 38517242
Drug: Anakinra treatment
RxNorm normalized name: anakinra
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Anakinra treatment
Trial: 35715405
Drug: Pembrolizumab with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab with chemotherapy
Trial: 33151266
Drug: CTC-driven treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CTC-driven treatment choice (chemotherapy if ≥5 CTCs/7.5 mL; endocrine therapy if <5 CTCs/7.5 mL)
Trial: 35498050
Drug: L-Arginine
RxNorm normalized name: L-Arginine
DrugBank: L-arginine (DB17289)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-Arginine
Trial: 34788571
Drug: Golodirsen 30
RxNorm normalized name: golodirsen
DrugBank: Golodirsen (DB15593)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Golodirsen 30 mg/kg
Trial: 32621905
Drug: Integrated behavior
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Integrated behavior therapy (video-based behavioral weight loss program and problem-solving therapy for depression)
Trial: 36342151
Drug: Double sequential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double sequential external defibrillation (DSED)
Trial: 34863776
Drug: RLRL treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RLRL treatment plus single-vision spectacle (SVS)
Trial: 34863776
Drug: RLRL treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RLRL treatment
Trial: 32202637
Drug: Acalabrutinib 100
RxNorm normalized name: acalabrutinib 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acalabrutinib 100 mg twice daily (BID)
Trial: 32202637
Drug: Acalabrutinib 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acalabrutinib 200 mg once daily (QD)
Trial: 35764522
Drug: Acupoint catgut
RxNorm normalized name: CATGUT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupoint catgut embedding combined with quadruple therapy
Trial: 35764522
Drug: Oral Weifuchun
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Weifuchun Tablets with quadruple therapy
Trial: 32388694
Drug: Control participants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control participants received home-based EHS plus 10 weekly books
Trial: 34563096
Drug: NUDT15 genotype-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NUDT15 genotype-based dose optimisation (50% dose reduction for CT genotype, alternative drugs for TT genotype)
Trial: 34460948
Drug: Dupilumab (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dupilumab (300 mg weekly subcutaneous)
Trial: 34460948
Drug: Dupilumab (in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dupilumab (in patients with baseline IgE ≥ 200 IU/ml)
Trial: 37060024
Drug: ACE inhibitors
RxNorm normalized name: ACE INHIBITORS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE inhibitors (ACEIs)
Trial: 34231846
Drug: DADEE intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: DADEE intervention (9-week program with weekly sessions plus home-based tasks)
Trial: 34537124
Drug: TAP block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAP block using 20-cc 0.5% bupivacaine solution
Trial: 34537124
Drug: p-TAP (placebo)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: p-TAP (placebo) using 20-cc isotonic solution
Trial: 34284344
Drug: DCVAC/LuCa and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DCVAC/LuCa and chemotherapy (carboplatin and paclitaxel)
Trial: 34284344
Drug: DCVAC/LuCa, chemotherapy,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DCVAC/LuCa, chemotherapy, pegylated interferon‐?2b, and hydroxychloroquine
Trial: 32728771
Drug: Low-dose computed
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose computed tomography (LDCT) lung cancer screening
Trial: 34090781
Drug: Regenerative cell
RxNorm normalized name: Regener-Eyes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regenerative cell therapy
Trial: 32833128
Drug: Aerobic exercise
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aerobic exercise (150 min of moderate-intensity weekly exercise)
Trial: 35590284
Drug: Oral pivmecillinam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral pivmecillinam (PIV) 400 mg QID for 1 week after 3 days of parenteral antibiotics
Trial: 34375336
Drug: Oral rotavirus
RxNorm normalized name: rotavirus vaccine, live attenuated, G1P[8] human 89-12 strain Oral Suspension [Rotarix]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral rotavirus vaccine
Trial: 34375336
Drug: Multiple micronutrient
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple micronutrient supplement (MMS)
Trial: 32917784
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg lanthanum carbonate thrice daily for 96 weeks
Trial: 32917784
Drug: Matched placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo thrice daily for 96 weeks
Trial: 32184305
Drug: WEE1 inhibitor
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: WEE1 inhibitor adavosertib (AZD1775) in combination with cisplatin chemotherapy preoperatively (group A)
Trial: 32184305
Drug: WEE1 inhibitor
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: WEE1 inhibitor adavosertib (AZD1775) in combination with postoperative cisplatin-based chemoradiation (group B)
Trial: 32184305
Drug: WEE1 inhibitor
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: WEE1 inhibitor adavosertib (AZD1775) in combination with cisplatin chemotherapy (group A)
Trial: 33955686
Drug: GLPG1205 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLPG1205 100 mg once daily for 12 days
Trial: 33812492
Drug: Aspirin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (100 mg per day) plus Mesalazine (2 g per day)
Trial: 33812492
Drug: Aspirin placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin placebo plus Mesalazine (2 g per day)
Trial: 33812492
Drug: Aspirin placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin placebo plus Mesalazine placebo
Trial: 35732417
Drug: Shufeng Jiedu
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shufeng Jiedu capsule (SFJDC) for 7 days
Trial: 36210622
Drug: 1 mmol/L
RxNorm normalized name: cardiopleg/organ preserv no.1 9 mmol-198 mmol-2 mmol-1 mmol/L PERFUSION BOTTLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mmol/L citrate
Trial: 36210622
Drug: 3 mmol/L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mmol/L acetate
Trial: 32150758
Drug: Non-TEE-guided strategy
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-TEE-guided strategy (edoxaban 60 mg once-daily or enoxaparin-warfarin)
Trial: 33497075
Drug: Periarticular injection
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Periarticular injection of corticosteroids (40 mg triamcinolone acetonide during surgery, placebo intravenous administration)
Trial: 33497075
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of corticosteroids
Trial: 33497075
Drug: Periarticular injection
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Periarticular injection of corticosteroids
Trial: 34898155
Drug: Topical stabilized
RxNorm normalized name: respiratory syncytial virus pre-fusion F protein, A, recombinant, stabilized / respiratory syncytial virus pre-fusion F protein, B, recombinant, stabilized Injection [Abrysvo]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical stabilized cysteamine (st.Cys)
Trial: 32100043
Drug: Opiate analgesics
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opiate analgesics (medically prescribed or not)
Trial: 32100043
Drug: Opiate analgesics
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opiate analgesics (not medically prescribed)
Trial: 32165156
Drug: BAL-directed CF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAL-directed CF therapy
Trial: 32865375
Drug: Early rhythm
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early rhythm control (treatment with antiarrhythmic drugs or atrial fibrillation ablation)
Trial: 35882513
Drug: Medication (medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication (medical management)
Trial: 36294153
Drug: Partner support
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Partner support and initiating a planned quit attempt during treatment
Trial: 32571602
Drug: One-on-one hand
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One-on-one hand therapy in addition to the handout
Trial: 32681219
Drug: Intralesional meglumine
RxNorm normalized name: Meglumine
DrugBank: Meglumine (DB09415)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intralesional meglumine antimoniate (MA) weekly over 10 weeks
Trial: 35672873
Drug: Ultrasound-guided curettage
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided curettage combined with hysteroscopic electro-resection after injection of pituitrin
Trial: 35672873
Drug: Hysteroscopic electro-resection
RxNorm normalized name: ELECTRODE SPRAY,ELECTRO MIST
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hysteroscopic electro-resection after methotrexate chemotherapy
Trial: 34282125
Drug: Prolonged-exposure psychotherapy
RxNorm normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged-exposure psychotherapy with hydrocortisone augmentation
Trial: 34282125
Drug: Prolonged-exposure psychotherapy
RxNorm normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged-exposure psychotherapy without hydrocortisone augmentation
Trial: 33653149
Drug: Patching treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patching treatment for amblyopia
Trial: 36521097
Drug: Adjuvant treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant treatment
Trial: 34473373
Drug: Gender-specific instruction
RxNorm normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gender-specific instruction for female first responders (10 min oral delivery by a staff physician)
Trial: 38697182
Drug: Standard insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard insulin therapy
Trial: 39036300
Drug: Aspirin (control)
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin (control)
Trial: 34406364
Drug: Bimekizumab (640
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bimekizumab (640 mg at week 0, 320 mg every 2 weeks)
Trial: 35645073
Drug: WhatsApp-based oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WhatsApp-based oral health promotion programme
Trial: 32030723
Drug: Microwave therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microwave therapy
Trial: 34977534
Drug: Conventional Physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional Physical Therapy (PT)
Trial: 34977534
Drug: Digital Exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digital Exercise Therapy Application (DETA)
Trial: 32213768
Drug: Na2FPO3/CaCO3 fluoride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Na2FPO3/CaCO3 fluoride toothpaste (1,378 µg F/g total soluble fluoride)
Trial: 32213768
Drug: Aged fluoride
RxNorm normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aged fluoride toothpaste (1,160 µg F/g total soluble fluoride)
Trial: 32213768
Drug: Aged fluoride
RxNorm normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aged fluoride toothpaste (900 µg F/g total soluble fluoride)
Trial: 32213768
Drug: Aged fluoride
RxNorm normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aged fluoride toothpaste (597 µg F/g total soluble fluoride)
Trial: 33145642
Drug: Otelixizumab 27
RxNorm normalized name: Otelixizumab
DrugBank: Otelixizumab (DB05496)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Otelixizumab 27 mg
Trial: 33662243
Drug: Animal Assisted
RxNorm normalized name: animals
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Animal Assisted Therapy (AAT) with an emotional support canine in the child's lap
Trial: 33168129
Drug: Home treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home treatment (HT) during the RCT study phase
Trial: 33168129
Drug: Home treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home treatment (HT) under routine care conditions
Trial: 33168129
Drug: Hospital ward
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hospital ward treatment